Literature DB >> 21837494

[Urothelial carcinoma].

H Rübben1, F Vom Dorp.   

Abstract

Various study groups are working on the WHO classification of 2004 which eliminates the previous grades of differentiation G1, G2, and G3 and classifies non-muscle-invasive bladder cancer into genetically stable low-grade and genetically unstable high-grade urothelial carcinomas. In muscle-invasive bladder cancer, extended lymph node dissection as part of radical cystectomy should remain the standard procedure for now.

Entities:  

Mesh：

Year:  2011        PMID： 21837494     DOI： 10.1007/s00120-011-2669-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  15 in total

1.  Is maintenance Bacillus Calmette-Guérin really necessary?

Authors:  Harry W Herr
Journal:  Eur Urol       Date:  2008-06-25       Impact factor: 20.096

2.  Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.

Authors:  Arnulf Stenzl; Hannes Penkoff; Elfriede Dajc-Sommerer; Andreas Zumbraegel; Lorenz Hoeltl; Michael Scholz; Claus Riedl; Josef Bugelnig; Alfred Hobisch; Maximilian Burger; Gregor Mikuz; Uwe Pichlmeier
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

4.  [Lymphadenectomy for bladder cancer. Diagnostic and prognostic significance as well as therapeutic benefit].

Authors:  J Leissner
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

5.  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

Authors:  H Barton Grossman; Leonard Gomella; Yves Fradet; Alvaro Morales; Joseph Presti; Chad Ritenour; Unyime Nseyo; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

6.  Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

Authors:  Hans-Martin Fritsche; Maximilian Burger; Robert S Svatek; Claudio Jeldres; Pierre I Karakiewicz; Giacomo Novara; Eila Skinner; Stefan Denzinger; Yves Fradet; Hendrik Isbarn; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Derya Tilki; Wolfgang Otto; Umberto Capitanio; Jonathan I Izawa; Vincenzo Ficarra; Seth Lerner; Arthur I Sagalowsky; Mark Schoenberg; Ashish Kamat; Colin P Dinney; Yair Lotan; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2009-09-12       Impact factor: 20.096

7.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

8.  Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome.

Authors:  Derya Tilki; Oliver Reich; Pierre I Karakiewicz; Giacomo Novara; Wassim Kassouf; Süleyman Ergün; Yves Fradet; Vincenzo Ficarra; Guru Sonpavde; Christian G Stief; Eila Skinner; Robert S Svatek; Yair Lotan; Arthur I Sagalowsky; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2010-01-20       Impact factor: 20.096

9.  Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?

Authors:  Stefan Denzinger; Hans-Martin Fritsche; Wolfgang Otto; Andreas Blana; Wolf-Ferdinand Wieland; Maximilian Burger
Journal:  Eur Urol       Date:  2007-06-27       Impact factor: 20.096

10.  Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.

Authors:  Martin C Schumacher; Sten Holmäng; Thomas Davidsson; Bengt Friedrich; Jörgen Pedersen; N Peter Wiklund
Journal:  Eur Urol       Date:  2009-11-06       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.